Recent studies have demonstrated that genetic or pharmacological inhibition of YAP could repress CSC-like properties in vitro and attenuate tumor growth and CSC marker expression in ESCC xenograft models by directly activating its downstream target SOX9 [136]. The gene discussed is YAP1; the disease is esophageal squamous cell carcinoma.